Gosset Ownership
Public
Employees
~2519
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Vetoquinol General Information
Vetoquinol has a broad commercial portfolio of veterinary medicines and non-medicinal products targeting pain/inflammation, dermatology, hygiene/care, udder health, reproduction, cardio-nephrology, behavior management. Recent regulatory milestones include FDA approvals for Clevor (emetic agent) and UpCard CA1 (for canine pulmonary edema). The company continues to launch new products such as VetPowerment.[5]
Contact Information
Primary Industry
Veterinary
Corporate Office
Lure, Haute-Saône
France
France
Drug Pipeline
Drontal
CommercialKey Partnerships
Not specifically listed; the company collaborates with distributors worldwide but no major pharma co-development partnerships disclosed.
Vetoquinol Funding
No funding data available
To view Vetoquinol's complete valuation and funding history, request access »
Vetoquinol Financial Metrics
Market Cap
$356.5M
Total Revenue
$32.3M